Yazar "Sucak, Gulsan" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Retrospective Evaluation of Patients Treated with Dasatinib for Philadelphia Positive Leukemias: Turkish Experience of 16 Months
    (Akad Doktorlar Yayinevi, 2009) Saydam, Güray; Haznedaroglu, Ibrahim C.; Temiz, Yesim; Soysal, Teoman; Sucak, Gulsan; Tombuloglu, Murat; Ozdogu, Hakan; Yavuz, Selim; Altintas, Abdullah; Ozet, Gulsum; Gulbas, Zafer; Ferhanoglu, Burhan; Ilhan, Osman
    This retrospective study was conducted on 114 CML patients with a mean treatment duration of 7.94 +/- 4.53 months. Disease status distribution among patients was 78.1% in chronic, 7.9% in accelerated, 14% in blastic phases. The last imatinib doses in chronic, accelerated and blastic phases were 609.72 +/- 171.29, 714.29 +/- 106.90, and 569.23 +/- 160.13, respectively. Complete hematologic response was 66.3% and 44.4% in chronic and accelerated phases, respectively. Molecular response was evaluated by bcr/abl transcript levels in RT-PCR. Complete molecular response was 27.0% in chronic, 11.1% in accelerated and 18.8% in blastic phases. Of 99 patients 77 (77.8%) were alive. 16th month-OS for 99 patients was 78% in Kaplan-Meier survival analysis. No adverse event was reported in 69.2% of patients, whereas disease progression and grade 1-2 myelosupression were the most frequently reported events. Most patients had complete hematological response. Dasatinib treatment was well-tolerated and resulted in favorable outcomes with mostly mild side effects.
  • Küçük Resim Yok
    Öğe
    Retrospective Evaluation of Patients Treated with Dasatinib for Philadelphia Positive Leukemias: Turkish Experience of 16 Months
    (Akad Doktorlar Yayinevi, 2009) Saydam, Güray; Haznedaroglu, Ibrahim C.; Temiz, Yesim; Soysal, Teoman; Sucak, Gulsan; Tombuloglu, Murat; Ozdogu, Hakan; Yavuz, Selim; Altintas, Abdullah; Ozet, Gulsum; Gulbas, Zafer; Ferhanoglu, Burhan; Ilhan, Osman
    This retrospective study was conducted on 114 CML patients with a mean treatment duration of 7.94 +/- 4.53 months. Disease status distribution among patients was 78.1% in chronic, 7.9% in accelerated, 14% in blastic phases. The last imatinib doses in chronic, accelerated and blastic phases were 609.72 +/- 171.29, 714.29 +/- 106.90, and 569.23 +/- 160.13, respectively. Complete hematologic response was 66.3% and 44.4% in chronic and accelerated phases, respectively. Molecular response was evaluated by bcr/abl transcript levels in RT-PCR. Complete molecular response was 27.0% in chronic, 11.1% in accelerated and 18.8% in blastic phases. Of 99 patients 77 (77.8%) were alive. 16th month-OS for 99 patients was 78% in Kaplan-Meier survival analysis. No adverse event was reported in 69.2% of patients, whereas disease progression and grade 1-2 myelosupression were the most frequently reported events. Most patients had complete hematological response. Dasatinib treatment was well-tolerated and resulted in favorable outcomes with mostly mild side effects.